Fetal lung maturity assessment and corticosteroid therapy

The transition from placental support to independent breathing is one of the most important events in neonatal medicine. Before birth, the lungs must produce enough surfactant to reduce surface tension and prevent widespread alveolar collapse. When delivery occurs too early, surfactant deficiency can contribute to respiratory distress syndrome, mechanical ventilation, air-leak syndromes, and prolonged hospitalization.

Clinical teams have used biochemical and imaging methods to estimate fetal lung development, while antenatal corticosteroids have become a major intervention for reducing complications associated with preterm birth. These approaches answer different questions: testing estimates readiness for extrauterine breathing, whereas corticosteroids accelerate aspects of pulmonary and systemic maturation when premature delivery is likely.

The subject fits within the wider scientific and clinical interests represented by FAOPS 2020 archive, which documented a major meeting devoted to perinatal and neonatal medicine in Asia and Oceania. Current practice combines gestational age, the probability and timing of delivery, maternal conditions, fetal status, and local neonatal resources rather than relying on a single laboratory result.

Why lung maturity matters before birth

Fetal lungs begin producing surfactant during the second half of pregnancy, but clinically meaningful quantities may not be available until later gestation. Surfactant contains phospholipids and proteins that stabilize the alveoli during expiration. Insufficient surfactant increases the work of breathing and can cause diffuse atelectasis soon after birth.

Respiratory distress syndrome is most strongly associated with prematurity, particularly at earlier gestational ages. The risk is also influenced by diabetes, fetal growth restriction, male sex, cesarean birth without labor, and certain genetic or developmental conditions. Gestational age remains the most useful broad predictor, although it cannot capture every individual difference in pulmonary development.

Lung maturity should therefore be viewed as a continuum rather than a binary state. A fetus may have enough surfactant for spontaneous breathing but still face risks involving apnea, pulmonary vascular adaptation, temperature regulation, feeding, or glucose control. A reassuring lung assessment does not eliminate those other consequences of early birth.

How fetal lung maturity has been assessed

Historically, clinicians sampled amniotic fluid through amniocentesis and measured the lecithin-to-sphingomyelin ratio. Lecithin rises as pregnancy advances, while sphingomyelin changes less substantially, so a higher ratio generally indicates greater surfactant production. The presence of phosphatidylglycerol provided additional evidence of pulmonary maturation, particularly when the ratio was difficult to interpret.

Other laboratory approaches include lamellar body counts, fluorescence polarization, and amniotic-fluid optical density. Lamellar bodies are storage granules that contain surfactant; their concentration can correlate with maturity, although thresholds vary by analyzer and laboratory. Blood, meconium, and contamination from vaginal secretions may affect results, making specimen quality important.

Ultrasound measurements of fetal lung volume, thoracic dimensions, and lung-to-head ratios have been investigated as noninvasive alternatives. Fetal magnetic resonance imaging can provide detailed structural information and may help research into lung development, but it is not a routine replacement for clinical assessment. No imaging method currently offers a universally accepted threshold that should determine delivery by itself.

In contemporary obstetrics, invasive maturity testing is used far less often than it once was. Better pregnancy dating, effective corticosteroid protocols, and evidence that a test may not change management have shifted attention toward decision-making based on the likely timing of birth and the clinical indication for delivery.

Comparing available assessment approaches

The value of a fetal lung assessment depends on whether its result will change care. If severe preeclampsia, placental abruption, intrauterine infection, fetal compromise, or another urgent condition requires delivery, postponing birth to obtain a maturity result may place the pregnant patient or fetus at greater risk. Conversely, in a stable situation with uncertain dating or an elective delivery under consideration, additional information may occasionally be useful.

The table illustrates why a result should never be interpreted in isolation. A “mature” biochemical profile does not predict every respiratory or neonatal outcome, and an “immature” profile may not justify delaying a medically necessary birth. Local laboratory validation and consultation with maternal-fetal medicine and neonatology are essential whenever testing is considered.

What antenatal corticosteroids do

Antenatal corticosteroids accelerate fetal lung maturation and reduce the incidence and severity of respiratory distress syndrome. They also lower the risks of intraventricular hemorrhage and necrotizing enterocolitis in appropriately selected preterm infants. The treatment is most effective when birth occurs after some time has passed following administration, although partial exposure may still provide benefit when delivery is imminent.

Common regimens include two intramuscular doses of betamethasone given 24 hours apart or four doses of dexamethasone given at 12-hour intervals. Exact protocols may differ by national guidance and institutional policy. The decision should account for the probability of delivery within the next seven days, gestational age, contraindications, and the capacity to provide neonatal respiratory support.

A single course is generally recommended when preterm birth is likely in the established gestational-age window, commonly from 24 through 33 or 34 weeks, depending on guideline criteria. In selected late-preterm pregnancies, treatment may be considered between 34 weeks and 36 weeks plus six days when delivery is expected soon and the potential benefits outweigh risks. Late-preterm exposure requires particular attention to neonatal hypoglycemia.

Corticosteroids do not eliminate the need for surfactant replacement, continuous positive airway pressure, careful thermoregulation, or other newborn support. They also do not make an otherwise unsafe pregnancy safe to continue. If delivery is indicated, steroids should be administered when feasible without creating a harmful delay.

Timing, repeat courses, and clinical context

The greatest benefit generally occurs when birth takes place from roughly 24 hours to seven days after the first dose. However, obstetric emergencies should not be postponed simply to complete the course. Hospitals often establish rapid pathways so that the first dose can be given promptly when preterm delivery becomes likely.

A repeat or “rescue” course may be considered for a patient who remains at substantial risk of preterm birth after an earlier course, depending on gestational age, the interval since the initial treatment, and national recommendations. Repeated exposure is not automatically beneficial. Potential effects on fetal growth, infection risk, and long-term development must be weighed against the immediate respiratory advantages.

The indication for delivery remains central. In severe maternal hypertension, worsening organ dysfunction, significant bleeding, suspected infection, or nonreassuring fetal status, the safest course may be delivery with neonatal preparation. In less urgent circumstances, a short period for corticosteroid administration may be reasonable if maternal and fetal conditions permit.

Counseling should include the expected benefits and limitations of therapy. Families may also need information about respiratory support, feeding difficulties, monitoring for low blood glucose, and the possibility of admission to a neonatal intensive care unit. Broader family-centered care matters during this period; discussion of parental presence in neonatal intensive care can help teams address communication and bonding alongside medical treatment.

Situations requiring individualized judgment

Diabetes complicates the assessment because fetal hyperinsulinemia may delay surfactant production, while corticosteroids can substantially raise maternal and fetal glucose levels. A plan should include glucose monitoring and adjustment of diabetes treatment. The presence of diabetes alone does not provide a reason to ignore the standard indications for steroids, but it does change monitoring needs.

Infection presents another balance of risks. Corticosteroids may be appropriate in some cases when preterm delivery is expected, yet suspected chorioamnionitis or maternal sepsis requires urgent antimicrobial treatment and obstetric management. Steroids should never be used to mask clinical deterioration or delay source control and delivery when those actions are necessary.

Fetal growth restriction, multiple gestation, oligohydramnios, placental disease, and congenital anomalies may alter the expected response to treatment. A mature fluid profile cannot resolve these broader concerns. Likewise, genetic or structural findings may influence counseling about respiratory support, prognosis, and the goals of care; developments in genetic counseling are increasingly relevant to complex perinatal decision-making.

When viability is near the threshold recognized by a local institution, decisions should involve obstetrics, neonatology, nursing, anesthesia, and the family. The discussion should address survival, possible disability, intensive care procedures, and the parents’ values. A standardized protocol is useful, but it should support individualized counseling rather than replace it.

Practical priorities for care teams

The safest approach links assessment, treatment, and delivery planning. Before ordering a maturity test or administering steroids, clinicians should confirm the gestational age as accurately as possible, identify why preterm birth may occur, and estimate whether delivery is likely within the treatment window.

Useful priorities include:

• Confirm gestational age, dating evidence, and the probability of birth within seven days.
• Give antenatal corticosteroids promptly when guideline criteria are met and no urgent delivery must take precedence.
• Avoid invasive lung maturity testing when the result will not change management.
• Prepare for neonatal respiratory support, glucose monitoring, temperature control, and appropriate referral.
• Document maternal risks, fetal findings, counseling, and the planned timing of delivery.

Communication across disciplines is especially important when pregnancy complications evolve quickly. The neonatal team should know the timing and number of steroid doses, the indication for delivery, relevant maternal illnesses, suspected infection, and any fetal diagnosis. This information supports decisions about delivery-room stabilization and postnatal respiratory care.

Translating evidence into safer decisions

Fetal lung maturity assessment has educational and diagnostic value, but its role in modern practice is narrower than the name may suggest. Laboratory tests measure selected biochemical features of surfactant; they do not provide a complete forecast of neonatal adaptation. Gestational age, clinical risk, and the reason for delivery often offer more actionable information.

Antenatal corticosteroids are among the most effective interventions for reducing serious complications of threatened preterm birth. Their use is strongest when the likelihood of delivery is high, the gestational age is appropriate, and the care team can monitor maternal and newborn effects. Treatment should be integrated with—not substituted for—careful obstetric planning and neonatal preparation.

Clinicians, educators, and families can use the evidence summarized here to review local protocols, improve timely referrals, and make shared decisions before an urgent delivery occurs. Apply the principles to each pregnancy, coordinate obstetric and neonatal expertise, and ensure that every eligible patient receives prompt, informed care.